Karen Flynn Buys Shares of Stevanato Group S.p.A.
Karen Flynn acquired 4,975 shares of Stevanato Group on June 12, 2026.
Key Points
- Karen Flynn purchased 4,975 shares of Stevanato Group S.p.A. on June 12, 2026, as part of an insider transaction.
- Stevanato Group shares traded near $18.39 on Friday, with a market cap of $5.02 billion and a P/E ratio of 31.7.
- Conestoga Capital Advisors increased its holdings by 602,050 shares, ending with 8,491,751 shares valued at $116.8 million.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Karen Flynn recently bought 4,975 shares of Stevanato Group S.p.A. (NYSE:STVN) on June 12, 2026. This insider transaction highlights her interest in the company, although the exact purchase price wasn't disclosed.
Other Institutional Activity in Stevanato Group
Conestoga Capital Advisors increased its holdings in Stevanato Group by 602,050 shares, ending with 8,491,751 shares worth about $116.8 million. Neuberger Berman Group reduced its position by 312,219 shares, holding 4,475,492 shares valued at $61.5 million. TimesSquare Capital Management slightly decreased its stake by 10,605 shares, resulting in 3,489,716 shares valued at $47.98 million. Meanwhile, T. Rowe Price Investment Management cut its shares by 698,724, leaving it with 3,224,908 shares worth $44.34 million. Bamco Inc. increased its position by 498,714 shares, holding 2,500,438 shares valued at $34.38 million.
Stevanato Group S.p.A. Stock Down 12.6%
Shares of Stevanato Group S.p.A. traded near $18.39 on Friday. The company has a market cap of $5.02 billion and a P/E ratio of 31.7. The stock's 52-week range is between $12.89 and $28.00, with a 50-day moving average of $17.39 and a 200-day moving average of $19.57. The company maintains a current ratio of 1.63 and a quick ratio of 1.11, with a debt-to-equity ratio of 29.43.
$STVN stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
In its most recent earnings report, Stevanato Group S.p.A. reported revenue of $1.20 billion, reflecting a growth of 6.6%. The company's earnings per share stood at $0.58, with a net margin of 11.75% and a return on equity of 9.59%. The next earnings report is expected on May 7, 2026.
Dividend
Stevanato Group pays an annual dividend rate of $0.06, yielding 0.34%, with a payout ratio of 10.59%.
Insider Buying and Selling at Stevanato Group S.p.A.
On June 12, 2026, Karen Flynn purchased 4,975 shares of Stevanato Group. Other insiders, including William Federici, Madhavan Balachandran, and Donald Morel Jr., each sold 1,493 shares at an average price of $17.09 on June 15, 2026. Additionally, Marco Dal Lago, the Chief Financial Officer, bought 2,356 shares on June 12, 2026.
Analysts Set New Price Targets
On June 16, 2026, TD Cowen initiated coverage of Stevanato Group with a "buy" rating and a $25.00 price target. Earlier, on June 2, 2026, Wolfe Research assumed coverage with a "buy" rating and a $21.00 target. The consensus among analysts is a "buy" rating, with a mean target price of $24.45 based on 10 opinions.
About Stevanato Group S.p.A.
Stevanato Group S.p.A. is a healthcare company based in Piombino Dese, Italy. It specializes in designing, producing, and distributing products and solutions for the biopharmaceutical and healthcare industries worldwide. The company operates through two segments: Biopharmaceutical and Diagnostic Solutions, and Engineering. It offers a range of products including pre-fillable syringes, vials, and drug delivery systems. Founded in 1949, Stevanato Group serves various clients, including pharmaceutical and biotech companies.
Bottom Line
Karen Flynn's recent purchase of Stevanato Group shares is a notable insider transaction. Investors often track such moves for potential signals about a company's prospects. Stevanato Group remains a significant player in the healthcare sector, with institutional investors like Conestoga Capital Advisors actively adjusting their positions. As always, insider transactions are just one piece of the investment puzzle.
Get Stevanato Group S.p.A. alerts
New 13F filings, insider trades, and analyst moves on $STVN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.